BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 8696717)

  • 1. Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report.
    Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T
    Lung Cancer; 1996 Feb; 14(1):135-44. PubMed ID: 8696717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study.
    Steward WP; Dunlop DJ; Cameron C; Talbot DC; Kleisbauer JP; Thomas P; Guerin JC; Perol M; Sanson C; Dabouis G
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():33-7. PubMed ID: 8718423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
    Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
    Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
    Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T; Schulz M
    J Clin Oncol; 1996 May; 14(5):1656-62. PubMed ID: 8622085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
    Castellano D; Lianes P; Paz-Ares L; Hidalgo M; Guerra JA; Gómez-Martín C; Gómez H; Calzas J; Cortés-Funes H
    Ann Oncol; 1998 Apr; 9(4):457-9. PubMed ID: 9636840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8.
    Akcali Z; Calikusu Z; Sakalli H; Ozyilkan O
    Tumori; 2008; 94(4):474-80. PubMed ID: 18822681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
    Crinò L; Scagliotti G; Marangolo M; Figoli F; Clerici M; De Marinis F; Salvati F; Cruciani G; Dogliotti L; Pucci F; Paccagnella A; Adamo V; Altavilla G; Incoronato P; Trippetti M; Mosconi AM; Santucci A; Sorbolini S; Oliva C; Tonato M
    J Clin Oncol; 1997 Jan; 15(1):297-303. PubMed ID: 8996156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
    Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
    Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.
    Huisman C; Giaccone G; van Groeningen CJ; Sutedja G; Postmus PE; Smit EF
    Lung Cancer; 2001; 33(2-3):267-75. PubMed ID: 11551422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Burkes RL; Cormier Y; Crump M; Feld R; Strack T; Schulz M
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):48-54. PubMed ID: 8893882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
    Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study.
    Einhorn LH
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-24-S8-26. PubMed ID: 9207312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
    Antón A; Díaz-Fernández N; González Larriba JL; Vadell C; Masutti B; Montalar J; Barneto I; Artal A; Rosell R
    Lung Cancer; 1998 Nov; 22(2):139-48. PubMed ID: 10022221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
    Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.